# IMpower010 (NCT02486718)

> Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02486718
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Atezolizumab; Cisplatin; Vinorelbine; Docetaxel; Gemcitabine; Pemetrexed
- Enrollment: 1280
- Primary outcome: Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population
- Primary outcome: DFS in All Randomized Stage II-IIIA Population
- Primary outcome: DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses IMpower010’s design and evaluation of adjuvant atezolizumab after resection and chemotherapy, including staging and PD-L1 subgroup analyses. Discussion covers how to interpret reported overall-survival trends alongside disease-free survival, whether immunotherapy use after recurrence affects that interpretation, and how subgroup findings relate to regulatory decisions and comparisons with PEARLS and KEYNOTE-091. It also discusses treatment costs and raises questions about optimal endpoints, chemotherapy’s role, and the place of adjuvant versus neoadjuvant immunotherapy.

## Indexed commentary on IMpower010 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 128
- Podcasts: 71
- YouTube: 55
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=impower010-nct02486718

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02486718", "email": "<work email>"}; the inbox owner confirms by the emailed link.